Fischer Medical Ventures and Nervotec (Nervotec), a Singaporean business, have established a worldwide cooperation aimed at transforming healthcare screening via contactless video-based vital sign monitoring.
As the first firm to manufacture such cutting-edge medical imaging equipment in India, Fischer Medical Ventures Limited (Fischer MVL) is well-known for its innovative efforts in producing high-quality Magnetic Resonance Imaging (MRI) systems.
In addition to medical imaging, Fischer MVL offers a wide range of ground-breaking diagnostic options, among which is Nervotec’s cutting-edge health screening—which eliminates the need for wearables or contact—that works flawlessly. Fischer MVL to finalize the strategic alliance to promote their game-changing technology on a worldwide scale.
A Singaporean company called Nervotec uses wearables-free contactless technology to enable predictive healthcare. Using any camera-enabled device, such as a smartphone, laptop, tablet, or even a person’s face, its novel solution uses artificial intelligence and remote photoplethysmography (rPPG) technology to measure physiological biomarkers like heart rate, heart rate variability, respiration rate, oxygen saturation, stress scores, and even blood pressure.
Nervotec’s algorithms can examine a user’s vitals in only a few minutes by merely having them gaze at their camera-enabled smartphone. This eliminates the need for wearables or invasive treatments. Nervotec’s method, which has been clinically verified in Singapore, is a ground-breaking way to enable widespread screening for early identification and intervention since it is quick, accurate, and affordable, noted its official release.
Nervotec is always pushing the envelope, and recently it achieved a first-in-the-world breakthrough by integrating clinically validated measurements of hemoglobin (used to measure anemia and detect Thalassemia) and HbA1C (average glucose level over time) into its extensive health monitoring suite.
With its contactless technology, to analyze samples that once required bottles of blood and a substantial amount of time, and to receive findings in a matter of minutes.
Ravindran Govindan, Executive Chairman & MD of Fischer MVL, expressed his enthusiasm about the collaboration: “We are elated to partner with Nervotec, a pioneer and leader in contactless vital signs monitoring that will redefine healthcare delivery worldwide. Not everyone has wearables, but most of us have a camera phone to enable Nervotec’s technology for regular monitoring of their own health and support mass screening faster and more cost effective.
“We are excited about the potential of rPPG technology beyond HbA1C to detect irregular heartbeats and detection of cardiovascular disease, combined with blood pressure and blood sugar levels to determine the overall health of individuals worldwide. Nervotec’s solutions complement our portfolio of medical devices and diagnostic solutions, and will create great value for our customers and stakeholders, added Ravindran.”
Jonathan Lau, Co-founder and CEO of Nervotec, emphasized the transformative potential of their technology, “With the high prevalence of undetected conditions such as hypertension and diabetes, we believe Nervotec’s innovative solution can truly make a difference in the well-being of billions of people globally. By identifying health risks before they escalate, Nervotec’s technology empowers individuals, healthcare providers, and employers to take timely action. This partnership with Fischer MVL enables us to expand our reach and deliver impactful health insights across various sectors, from workplace safety to personalized healthcare.”
Through this strategic agreement, the duo has the potential to completely transform healthcare delivery worldwide. Combined with Fischer MVL’s extensive experience in medical equipment and solutions, strong resources, and global strategic network.
